Abstract
The design, synthesis, structure and the antimycobacterial activities of a new class of nitrogen heterocycles, namely N1-substituted-diphenyl ether-bis-pyridazine (BP), is presented. An efficient, facile and straight applicable method for preparation of BP derivatives is described. The primary cycle high throughput screening reveals that two BP compounds, 2a and 3b, are potent inhibitors against Mycobacterium tuberculosis (Mtb), with their antitubercular activity being superior to the second-line antitubercular drug Pyrimethamine and being equal to Cycloserine. The data from cycle-2 screening confirm the results from cycle-1. The MIC, MBC, LORA, intracellular (macrophage) drug screening, and MTT cell proliferation, indicate the intracellular drug effectiveness against Mtb of these compounds, the lack of toxicity, a significant activity against both replicating and non-replicating Mtb and, a bactericidal mechanism of action (for 2b). SAR correlations have been done. Overall, the BP derivatives and especially compound 2b, appeared as a new leading antitubercular structure, which makes it a promising lead for further drug development.
Keywords: Antimycobacterial, Bis-pyridazine, diphenyl ether linker, LORA, MBC, MIC, MTT, SAR.
Infectious Disorders - Drug Targets
Title:Design, Synthesis and Antimycobacterial Activity of Some New Pyridazine Derivatives: Bis-pyridazine. Part IV12-14
Volume: 13 Issue: 5
Author(s): Dorina Mantu, Vasilichia Antoci and Ionel I. Mangalagiu
Affiliation:
Keywords: Antimycobacterial, Bis-pyridazine, diphenyl ether linker, LORA, MBC, MIC, MTT, SAR.
Abstract: The design, synthesis, structure and the antimycobacterial activities of a new class of nitrogen heterocycles, namely N1-substituted-diphenyl ether-bis-pyridazine (BP), is presented. An efficient, facile and straight applicable method for preparation of BP derivatives is described. The primary cycle high throughput screening reveals that two BP compounds, 2a and 3b, are potent inhibitors against Mycobacterium tuberculosis (Mtb), with their antitubercular activity being superior to the second-line antitubercular drug Pyrimethamine and being equal to Cycloserine. The data from cycle-2 screening confirm the results from cycle-1. The MIC, MBC, LORA, intracellular (macrophage) drug screening, and MTT cell proliferation, indicate the intracellular drug effectiveness against Mtb of these compounds, the lack of toxicity, a significant activity against both replicating and non-replicating Mtb and, a bactericidal mechanism of action (for 2b). SAR correlations have been done. Overall, the BP derivatives and especially compound 2b, appeared as a new leading antitubercular structure, which makes it a promising lead for further drug development.
Export Options
About this article
Cite this article as:
Mantu Dorina, Antoci Vasilichia and Mangalagiu I. Ionel, Design, Synthesis and Antimycobacterial Activity of Some New Pyridazine Derivatives: Bis-pyridazine. Part IV12-14, Infectious Disorders - Drug Targets 2013; 13 (5) . https://dx.doi.org/10.2174/1871526514666140217144707
DOI https://dx.doi.org/10.2174/1871526514666140217144707 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacophore Modeling Methods in Focused Library Selection – Applications in the Context of a New Classification Scheme
Combinatorial Chemistry & High Throughput Screening Pharmacogenetics Research Developments in Africa: A Focus on Malawi
Current Pharmacogenomics and Personalized Medicine Increased Expression of Forkhead Box Protein 3 Gene of Regulatory T Cells in Patients with Active Tuberculosis
Inflammation & Allergy - Drug Targets (Discontinued) A Novel Finding: Macrophages Involved in Inflammation Participate in Acute Aortic Dissection Complicated with Acute Lung Injury
Current Molecular Medicine High Throughput Crystallography of TB Drug Targets
Infectious Disorders - Drug Targets Microwave: An Important and Efficient Tool for the Synthesis of Biological Potent Organic Compounds
Current Medicinal Chemistry Evolving Larger: Dosing Anti-Tuberculosis (TB) Drugs in an Obese World
Current Pharmaceutical Design Recent Advances on Isoniazide Derivatives
Anti-Infective Agents in Medicinal Chemistry Role of Open Source Tools and Resources in Virtual Screening for Drug Discovery
Combinatorial Chemistry & High Throughput Screening Scorpion Extracts Inhibit Tumor Growth in Esophageal Cancer and Lung Adenocarcinoma
Current Signal Transduction Therapy Attack on the Scourge of Tuberculosis: Patented Drug Targets
Recent Patents on Anti-Infective Drug Discovery Patent Selections
Recent Patents on Anti-Infective Drug Discovery Bioactive Peptides from Marine Sources as Potential Anti-Inflammatory Therapeutics
Current Protein & Peptide Science Meet Our Editorial Board Member
Current Medicinal Chemistry LYS70 of E. coli Quinolinate Phosphoribosyltransferase Is Protected from Chemical Modification by Formation of an Inhibitor Complex.
Protein & Peptide Letters Heterocycles in the Treatment of Neglected Tropical Diseases
Current Medicinal Chemistry Synthesis and In Vitro Evaluation of Novel 1, 2, 4-Triazole Derivatives as Antifungal Agents
Letters in Drug Design & Discovery Dendritic Cells in Innate Immune Responses Against HIV
Current Molecular Medicine A Review of Molecular Modelling Studies of Dihydrofolate Reductase Inhibitors Against Opportunistic Microorganisms and Comprehensive Evaluation of New Models
Current Pharmaceutical Design Patent Selections
Recent Patents on Biotechnology